Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2010
09/21/2010CA2545821C Aroylfuranes and aroylthiophenes
09/21/2010CA2538884C Quinazoline derivatives as tyrosine kinase inhibitors
09/21/2010CA2499429C Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
09/21/2010CA2481229C Substituted pyrazine inhibitors of akt
09/21/2010CA2458415C 24-sulfur-substituted analogs of 1.alpha.,25-dihydroxy vitamin d3
09/21/2010CA2445068C Azo compounds for type i phototherapy
09/21/2010CA2434308C Synthesis of temozolomide and analogs
09/21/2010CA2434178C Substituted amine derivatives and methods of use
09/21/2010CA2428019C Estrogen receptor modulators
09/21/2010CA2420568C Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
09/21/2010CA2417148C Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
09/21/2010CA2405002C Antitumoral analogs of et-743
09/21/2010CA2404235C Cell-specific adenovirus vectors comprising an internal ribosome entry site
09/21/2010CA2387539C Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
09/21/2010CA2369292C Method of modulating the activity of functional immune molecules
09/21/2010CA2345659C Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
09/21/2010CA2338073C Novel urokinase inhibitors
09/21/2010CA2327835C Methods and modified cells for the treatment of cancer
09/21/2010CA2307142C N-terminally chemically modified protein compositions and methods
09/21/2010CA2234941C Delivery of biologically active polypeptides
09/21/2010CA2225788C Therapeutic agents and autoimmune diseases
09/18/2010CA2697169A1 Compositions and methods for augmenting activity of oncolytic viruses
09/16/2010WO2010105243A1 Methods and compositions for cell-proliferation-related disorders
09/16/2010WO2010105110A1 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
09/16/2010WO2010105082A1 Treatment of pancreatic cancer
09/16/2010WO2010105016A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
09/16/2010WO2010105008A2 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
09/16/2010WO2010104945A1 Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
09/16/2010WO2010104819A2 Hollow gold nanospheres (haunss) and haunss-loaded microspheres useful in drug delivery
09/16/2010WO2010104749A2 Antigen presenting cell targeted cancer vaccines
09/16/2010WO2010104691A2 Estrogenic compounds and their methods of use
09/16/2010WO2010104598A2 Kinase protein binding inhibitors
09/16/2010WO2010104588A2 Compositions and methods for characterizing and treating neoplasia
09/16/2010WO2010104406A1 Prodrug forms of kinase inhibitors and their use in therapy
09/16/2010WO2010104253A1 Multifunctional contrast agent using biocompatible polymer and preparation method
09/16/2010WO2010104205A1 7-cycloalkylaminoquinolones as gsk-3 inhibitors
09/16/2010WO2010104147A1 Antioxidant agent
09/16/2010WO2010104035A1 Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer
09/16/2010WO2010104024A1 Piperazine compound capable of inhibiting prostaglandin d synthase
09/16/2010WO2010103851A1 Method for determining sensitivity to irinotecan and use thereof
09/16/2010WO2010103684A1 Sequence-specific expression regulator which targets at myc downstream gene, and method for determining target or targets of myc downstream gene
09/16/2010WO2010103486A1 Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof
09/16/2010WO2010103338A1 Analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and n-acyl derivatives for tumour treatment
09/16/2010WO2010103240A1 10-amino-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6(10bh)-one derivatives, method for preparing same, and therapeutic uses thereof
09/16/2010WO2010103095A1 Tetrahydronaphthalen-2-ol derivatives
09/16/2010WO2010103046A1 N-hydroxy c29-amide derivatives of oleandrane
09/16/2010WO2010102958A1 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
09/16/2010WO2010102937A1 Covalent milk protein/isothiocyanate complexes
09/16/2010WO2010102825A1 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
09/16/2010WO2010102788A1 Prodrugs
09/16/2010WO2010102673A1 Hellebrin and hellebrigenin derivatives
09/16/2010WO2010102518A1 Polymer of fusion proteins
09/16/2010WO2010102513A1 Homopiperazine acethydrazide derivatives, preparation method and uses thereof
09/16/2010WO2010102393A1 2-indolyl imidazo [4,5-d]phenanthroline derivatives and their use to inhibit angiogenesis
09/16/2010WO2010102363A1 Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites
09/16/2010WO2010088368A3 Imidazopyrazines as protein kinase inhibitors
09/16/2010WO2010074936A3 Enzastaurin for the treatment of cancer
09/16/2010WO2010068920A3 Diaminoquinazoline inhibitors of dihydrofolate reductase
09/16/2010WO2010065865A3 Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
09/16/2010WO2010065329A3 Nanoparticles for cancer treatment
09/16/2010WO2010062686A3 Imidazol-4-one and imidazole-4-thione compounds
09/16/2010WO2010059963A3 Preparation and methodology of silk fibroin nanoparticles
09/16/2010WO2010057596A3 New therapy and medicament using integrin ligands for treating cancer
09/16/2010WO2010057203A3 Hdl particles for delivery of nucleic acids
09/16/2010WO2010056737A3 Methods and compositions involving mirnas in cancer stem cells
09/16/2010WO2010056320A3 Pi3k/mtor kinase inhibitors
09/16/2010WO2010054285A3 Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
09/16/2010WO2010054056A3 Nilotinib hci crystalline forms
09/16/2010WO2009103807A8 Copper organocomplexes, use thereof as antitumor means and for protecting healthy tissue from ionizing radiation
09/16/2010US20100234599 Method for preparing acid addition salts of polyacidic basic compounds
09/16/2010US20100234578 Anti-cd40 monoclonal antibody
09/16/2010US20100234463 Method for Identifying Modulators of Gamma Secretase or Notch
09/16/2010US20100234456 Apoptosis promoters
09/16/2010US20100234455 Histone Deacetylase Inhibitors
09/16/2010US20100234451 Lna antagonists targeting the androgen receptor
09/16/2010US20100234450 Molecular targeting agents
09/16/2010US20100234448 In vivo production of small interfering rnas that mediate gene silencing
09/16/2010US20100234446 RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof
09/16/2010US20100234445 Patterns of known and novel small RNAS in human cervical cancer
09/16/2010US20100234423 Triazolothiadiazole inhibitor of c-met protein kinase
09/16/2010US20100234408 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
09/16/2010US20100234407 Preventives/remedies for myeloma tumor and method for diagnosing the same
09/16/2010US20100234406 Compounds and compositions as c-kit and pdgfr kinase inhibitors
09/16/2010US20100234404 P-38 Kinase Inhibitors
09/16/2010US20100234399 Agent for overcoming resistance to anti-cancer agent
09/16/2010US20100234397 Enzyme inhibitors
09/16/2010US20100234394 Substituted benzimidazoles and methods of their use
09/16/2010US20100234386 Quinoxaline derivatives as pi3 kinase inhibitors
09/16/2010US20100234383 Treating, preventing or ameliorating a hyperproliferative disease/disorder
09/16/2010US20100234381 Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
09/16/2010US20100234376 [4,5']Bipyrimidinyl-6,4'-Diamine Deriviatives as Protein Kinase Inhibitors
09/16/2010US20100234374 Heterocycle Substituted Ketone Derivatives as Histone Deacetylase (HDAC) Inhibitors
09/16/2010US20100234371 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
09/16/2010US20100234370 Pharmaceutical compounds
09/16/2010US20100234369 5-cyanothienopyridines for the treatment of tumours
09/16/2010US20100234367 7-cycloalkylaminoquinolones as gsk-3 inhibitors
09/16/2010US20100234365 Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
09/16/2010US20100234354 Pyridazinone derivatives
09/16/2010US20100234353 Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
09/16/2010US20100234351 Fused nitrogen-comprising heterocyclic compound
1 ... 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 ... 2211